The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1615
January 11, 2021
View Complete Issue         Table of Contents 2019 
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
January 11, 2021 (Issue: 1615)
The oral polymerase acidic endonuclease inhibitor baloxavir marboxil (Xofluza — Genentech) is now FDAapproved for post-exposure prophylaxis of influenza in patients ≥12 years old. Baloxavir was approved for treatment of acute uncomplicated...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Baloxavir (Xofluza) for Post-Exposure Prophylaxis of Influenza
Article code: 1615b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.